"Mei" Tian New Drug Developments and Corporate Updates as of July 22

Jul 22, 2024 07:30 CST Updated 07:30

Hengrui Pharma

Innovative and High-Quality Pharmaceutical Developer

Hansoh Pharma

Innovative Therapeutic Drug Developer

CHIATAI TIANQING

High-quality pharmaceuticals research, production, and sales provider

Apeiron

Pharmaceutical R&D Developer

On July 21, Hengrui Pharma announced that the company had received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the drug Hetrombopag Ethanolamine Tablets, and will soon commence clinical trials. Hetrombopag Ethanolamine Tablets have been approved for two indications: in June 2021, it was approved by the National Medical Products Administration for the treatment of adult patients with chronic primary immune thrombocytopenia who had previously shown inadequate response to treatments such as glucocorticoids and immunoglobulins, as well as for the treatment of adult patients with severe aplastic anemia who showed poor response to immunosuppressive therapy.

On July 19, according to the official website of CDE, Shanghai Yingpai Pharmaceutical Co., Ltd. jointly applied for the drug "IMP9064 Tablets," and obtained clinical trial implied permission. The indication is proposed for the treatment of advanced solid tumors.

On July 19, according to the CDE official website, Hansoh Pharma's third indication for Aumolertinib has been accepted for marketing application. The speculated indication may be: adjuvant treatment of epidermal growth factor receptor (EGFR) sensitive mutation non-small cell lung cancer (NSCLC) (Acceptance No.: CXHS2400060).

On July 19, the CDE website showed that Chia Tai Tianqing Pharmaceutical Group Co., Ltd. submitted marketing applications for two innovative drugs: Class 1 new drug Cumoxil Capsules, a CDK2/4/6 inhibitor; and Class 2.4 new drug Fulvestrant Injection, an estrogen receptor (ER) down-regulator. The indication applied for marketing approval is: Cumoxil Capsules combined with Fulvestrant Injection for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer previously treated with endocrine therapy.

Investment and Financing in Pharmaceuticals

July 19 News: Apeiron Therapeutics announced that it has reached an agreement with Exscientia to sell 50% of its rights to the highly selective oral CDK7 inhibitor GTAEXS617 to Exscientia. According to the agreement, Apeiron will receive a transaction consideration valued at $30 million, including $10 million in cash, $10 million worth of Exscientia shares, and high single-digit royalties from the project's out-licensing, with a potential value exceeding $100 million. Additionally, Exscientia will assume all ongoing research and development expenses for GTAEXS617.

Technology-Driven Drug Research

On July 18, the He Aibin team from Peking University's Future Technology Academy/Peking University-Tsinghua University Joint Center for Life Sciences/Peking University Cancer Hospital/Peking University Chengdu Frontier Interdisciplinary Biotechnology Institute, in collaboration with the Shu Shaokun team from Peking University International Cancer Research Institute/Peking University Cancer Hospital, published a research article titled "Single-cell EpiChem jointly measures drug-chromatin binding and multimodal epigenome" online in Nature Methods. The paper reports a novel high-throughput single-cell multi-omics technology called scEpiChem (Single Cell co-assay of Epigenome and small molecule Chemicals). This method can simultaneously capture genome-drug target interactions and multimodal epigenetic states at the single-cell level, elucidating drug responses, functional heterogeneity, and the molecular mechanisms of drug resistance.

[1]Xiong, H. et al. Single-cell joint detection of chromatin occupancy and transcriptome enables higher-dimensional epigenomic reconstructions. Nat Methods 18, 652-660 (2021).

Live Broadcast Preview